Yang Liu, MD
Hematology & Oncology · Maplewood, MNNPI 1285079988
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $237 of the $369 with a category attached, or 64.3%. 7 manufacturers reported payments, led by AbbVie at 32.5% of the total. Reporting peaked in 2022 at $139 and has fallen 67.4% since, to $45 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MN, where the typical reported total is $238.
Across 9 payments — averaging $41.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$120
- Foundation Medicine, Inc.$118
- Novartis$51
- Bayer$35
- Pharmaessentia USA Corporation$18
- Stemline Therapeutics Inc.$15
- plus $12 from 1 others
Across 5 payments — averaging $12,442 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$49K
- Novartis$11K
- Merck$2K
What the payments were for
- Grants$12032%
- Food & beverage$23764%
- Education$123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $120 |
| Foundation Medicine, Inc. | 1 | $118 |
| Novartis | 2 | $51 |
| Bayer | 2 | $35 |
| Pharmaessentia USA Corporation | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$369 in reported general payments places this provider in the 50th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InlytaAxitinib | 33 | $651,292 |
| IbrancePalbociclib | 40 | $609,369 |
| CalquenceAcalabrutinib Maleate | 23 | $335,730 |
| TukysaTucatinib | 12 | $295,773 |
| BrukinsaZanubrutinib | 21 | $280,497 |
| RevlimidLenalidomide | 18 | $261,465 |
| JakafiRuxolitinib Phosphate | 13 | $216,292 |
| TagrissoOsimertinib Mesylate | 13 | $204,629 |
| Lenalidomide | 18 | $195,981 |
| VerzenioAbemaciclib | 13 | $191,663 |
| ImbruvicaIbrutinib | 11 | $65,932 |
| EliquisApixaban | 95 | $61,344 |
| XareltoRivaroxaban | 40 | $43,626 |
| Abiraterone Acetate | 12 | $27,921 |
| Tamoxifen Citrate | 132 | $4,148 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Maplewood
- Vladimir HugecMaplewood$3K
- Mark RedingMinneapolis$519K
- Shilpa GuptaMinneapolis$421K
- Sagar PatelEdina$389K
- Vicki MorrisonMinneapolis$354K
- Deepti BehlRochester$205K
- Yan JiSaint Paul$164K
- Aimee MerinoMinneapolis$161K
- Yucai WangRochester$77K
- Purvi GadaChaska$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.